The company filed a material 8-K report with the SEC, so the model re-ran its full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › CTRE
Caretrust Reit, Inc. (CTRE) stock analysis
WEAK BUY 15% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Caretrust Reit, Inc. (CTRE) WEAK BUY with 15% confidence at a price of $36.26. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$36.26
Technical picture
The 14-day RSI is 52, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is only 0.8x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $43.16 and the swing low is $32.64; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 62.2% and revenue growth of +43.5%.
In its latest quarter it earned $0.39 per share, which matched the $0.39 analysts expected, with revenue +42.8% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $43.64.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $36.26, a target of $37.30 (+2.9%) and a stop-loss at $34.60 (-4.6%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 4, 2026 whatever the price does.
Entry$36.26
Target$37.30
Stop-loss$34.60
Reassess byNov 4, 2026
Research notes
CTRE’s bull case is driven by healthcare real-estate expansion: the company has raised 2026 FFO guidance to $2.06–$2.09, announced a $400 million skilled-nursing portfolio acquisition, and has a $600 million investment pipeline. The bear case is valuation and execution risk—shares trade near $37 while the average analyst target is about $43.64, but Barron’s rates the stock only “Hold” and describes fundamentals as average. A major recent catalyst is CTRE’s agreement to acquire 45 U.K. care homes for £1.1 billion, alongside BlackRock’s reported 15.7% ownership stake. The next key event is third-quarter earnings, expected after the close on November 5, with consensus estimates of $133.3 million revenue and $0.40 EPS.
The model's one-paragraph read
Leans BUY — composite score +0.15 (WEAK BUY). Technicals: RSI 51.63, MACD bullish, price below SMA50. Fundamentals: margin 62.2%, revenue growth 43.5%. Financial results: YoY revenue +42.8%, last EPS surprise +0.0%, next earnings 2026-11-05. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block, sitting inside an unfilled bearish fair value gap. FinGPT news read: positive. Internet research: CTRE’s **bull case** is driven by healthcare real-estate expansion: the company has raised 2026 FFO guidance to $2.06–$2.09, announced a $400 million skilled-nursing portfolio acquisition, and has a $600 million investment pipeline. The **bear case** is valuation and execution risk—shares trade near $37 while the average analyst target is about $43.64, but Barron’s rates the stock only “Hold” and describes fundamentals as average. A major recent catalyst is CTRE’s agreement to acquire 45 U.K. care homes for £1.1 billion, alongside BlackRock’s reported 15.7% ownership stake. The next key event is third-quarter earnings, expected after the close on November 5, with consensus estimates of $133.3 million revenue and $0.40 EPS. Suggested levels: entry $36.26, target $37.3, stop-loss $34.6, exit by 2026-11-04 (exit before next earnings (2026-11-05) -- this signal doesn't price in that report).
Past ratings for CTRE
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 15% | $36.26 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on CTRE
Oct 30, 2026 · Caretrust Reit, Inc. files an 8-K: material agreement
Frequently asked questions
Is CTRE a buy right now?
As of Oct 30, 2026, our automated model rates Caretrust Reit, Inc. (CTRE) WEAK BUY with 15% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for CTRE?
The model's most recent plan targets $37.30 with a stop-loss at $34.60, from an entry near $36.26.
When does Caretrust Reit, Inc. report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.